Ipamorelin
10 mg vial

$89.99 AUD, GST included
Minimum order before shipping, and you can mix any products to reach it.
In stock, ready to ship from Australia
Frequently ordered with
Bacteriostatic WaterSold to buyers aged 18 and over only.
Buy Tesamorelin online from AminoLab, available in Australia as the 5 mg vial, 10 mg vial or 20 mg vial. Tesamorelin Australia stock ships from AminoLab's local shelves in three freeze-dried fills, 5 mg, 10 mg and 20 mg. The molecule, developed under the code TH9507, keeps the human growth hormone releasing hormone chain complete at 44 amino acids and fits a trans-3-hexenoyl group onto the N-terminal tyrosine. That cap blocks fast DPP-4 cleavage yet leaves binding at the pituitary GHRH receptor intact. Reference values are CAS 218949-48-5, C221H366N72O67S and 5135.9 g/mol. Nothing ships without documentation, because each lot has its identity confirmed by mass spectrometry and its purity measured by HPLC, with the resulting certificate of analysis readable in the COA library ahead of checkout. Feed your diluent volume into the tesamorelin calculator for a working concentration. Buy tesamorelin Australia wide alongside sermorelin when the full chain needs comparing with the native 29-residue fragment. Powder arrives without diluent, so include bacteriostatic water. Sealed vials go to -20 °C out of the light. Secure your Tesamorelin from AminoLab now, available to researchers aged 18 and over for in vitro use.
For laboratory research use only. Not for human or veterinary use. Not TGA approved. See our research use policy.
| Listed as | Tesamorelin |
|---|---|
| Stock | In stock |
| Permitted use | Laboratory in vitro research only |
| Structure | Human GHRH (1-44) amide bearing a trans-3-hexenoyl group on Tyr1 |
| Chain | 44 amino acids |
| Empirical formula | C221H366N72O67S |
| Mass | 5135.9 g/mol |
| CAS registry | 218949-48-5 |
| How it ships | Freeze-dried powder, sealed glass vial, rubber stopper under a flip-off cap |
| Included | One vial at 5 mg, 10 mg or 20 mg, with no diluent supplied (bacteriostatic water sold separately) |
| Keep it at | -20 °C sealed, dark and dry, then 2 to 8 °C after reconstitution |
| Testing per lot | Identity by mass spectrometry, purity by HPLC, certificate issued |
Work that needs the whole GHRH sequence, not a shortened fragment, points to this vial. All three fills are held here in Australia, HPLC documents every lot, and the sizing section further down matches a fill to your study. Order your fill here and AminoLab ships it from Australian stock.
Take GHRH, the 44-residue hormone that turns on growth hormone output, synthesise it, then add a small fatty cap at the front so enzymes cannot pull it apart immediately. That is tesamorelin. The pituitary responds to it by releasing growth hormone on its normal rhythm. Among GHRH analogues it stands alone in having a completed phase 3 programme behind it.
DPP-4 attacks native GHRH between residues two and three, alanine and aspartic acid, and what remains after that cut is more or less inactive. The answer here is a trans-3-hexenoyl group, six carbons with a single double bond, attached to the first tyrosine. Crucially the cap sits away from the receptor-binding surface, so the molecule still engages the somatotroph GHRH receptor and triggers the same cyclic AMP signal, which empties the stored growth hormone.
For researchers the appeal lies in what this route preserves. Administer growth hormone itself and the control system is bypassed. Use a GHRH agonist and you act upstream, leaving somatostatin and IGF-1 free to restrain the pituitary, so output continues in pulses rather than flattening out.
Falutz and colleagues published the best known dataset in the New England Journal of Medicine in 2007. The trial ran 26 weeks and randomised 412 adults who had HIV together with abdominal fat accumulation, 275 of them to tesamorelin and 137 to placebo, measuring visceral fat on abdominal CT. The active group lost 27.8 square centimetres of visceral fat area while the placebo group gained 5.1 square centimetres, and the authors also noted improved lipid profiles. Liver fat in the same population was examined later by Stanley and colleagues. All of this evidence sits inside an HIV setting, and none of it extends to the compound outside that setting.
Our practical take is this. No other GHRH analogue has large controlled trials behind it, which makes tesamorelin the most defensible reference agonist when bench results have to be read next to the clinical literature. Just plan in moles rather than milligrams. At 5135.9 g/mol it outweighs sermorelin by roughly half again, so matching on an equimolar basis means roughly 1.5 times the mass. If you want a ghrelin receptor partner, the best peptide to pair with tesamorelin is already combined for you in the tesamorelin and ipamorelin vial. That record is why so many labs buy it from AminoLab as their reference GHRH agonist.
Montreal company Theratechnologies designed the molecule by keeping the human hormone whole, all 44 residues, and bonding a single hexenoyl cap to the first amino acid. Minutes are all native GHRH gets before DPP-4 cuts it, whereas the cap slows that cleavage and leaves receptor binding alone. United States approval followed in 2010 under the name Egrifta for a narrow indication, and the body of trial evidence behind that approval is a large part of why these tesamorelin peptides appear so often in published GH axis work.
At the bench the question becomes straightforward. What does the complete hormone do at the GHRH receptor once it survives long enough to measure? Our listing is a research reagent only, with no therapeutic standing and no TGA approval, grouped with the rest of our growth hormone peptides. Any tesamorelin peptide Australia order draws on one tested stockholding, whatever fill is chosen.
All three fills contain the same lyophilised white powder and nothing besides, waiting for whichever diluent you prefer. Phase 3 work by Theratechnologies ran through the 2000s while the compound still went by TH9507. Approval in the United States followed on 10 November 2010, the FDA clearing it under the name Egrifta for reducing excess abdominal fat where adults had HIV-associated lipodystrophy. America later saw two reformulations, Egrifta SV and then Egrifta WR, the latter cleared in March 2025, while in Europe the filing was pulled in 2012 before any decision.
No tesamorelin medicine ever reached this country. Searching the TGA's product information repository in October 2026 returns neither a tesamorelin nor an Egrifta document, we located no ARTG registration, and no pharmacy product can be dispensed on prescription. No individual Poisons Standard entry names tesamorelin, and none is needed. Under the June 2026 instrument the growth hormone releasing hormones are scheduled as a whole class, both in Schedule 4 and at clause 5 of Appendix D, and an analogue of GHRH (1-44) plainly falls inside it. Research suppliers are therefore the only realistic source for Australian laboratories.
Anti-doping rules treat it the same way as its relatives. The 2026 WADA Prohibited List groups tesamorelin with sermorelin and CJC-1295 among the GHRH analogues in class S2, and Sport Integrity Australia applies that prohibition at all times.
AminoLab holds all three sizes of tesamorelin for sale in Australian stock, as laboratory reagents. Only adults may check out, and the use permitted is in vitro research, not humans and not animals. For a shorter GHRH comparator on the bench beside it, most groups add the 10 mg CJC-1295 No DAC vial.
One specification covers all three vials, so the tesamorelin buy decision comes down to how much you need. Doubling up barely changes the invoice, which is why the tesamorelin 10mg vial is the usual opening order.
Several vials of one size can go through a single checkout and, where stock allows, they stay on one lot under one certificate. Labs that are unsure usually begin at 10 mg and move up once the method is stable. Only adults aged 18 and over may complete a purchase.
Spelled out the chain reads YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2, carrying the trans-3-hexenoyl group at Tyr1. Building 44 residues gives deletions and truncations more opportunity to appear than a short synthesis does, and such near-miss products often elute near the principal HPLC peak. Hence the mass figure deserves every bit as much attention as purity.
Confirm two items. One is a reported mass in line with 5135.9 g/mol. The other is an HPLC figure recorded against the lot code on your vial. The COA library indexes reports by that code, and our guide to reading a COA sets out how the pair of results fit together. Check both results before you order.
There is no walk-in counter at AminoLab, only an online store, and one domestic stockholding supplies every state and territory. Pay before 3pm on a business day and the vial leaves that afternoon, after which you can follow it on track order. A lab needing research peptides in Hobart draws on that same stock.
To reconstitute, bring the vial up to room temperature, add bacteriostatic water slowly against the glass, then swirl instead of shaking. For example, 2 mL into the 10 mg vial yields 5 mg/mL. Both the 5 mg and 20 mg fills, at any volume you like, are covered by the tesamorelin calculator.
Sealed vials are best at -20 °C inside their carton. Once mixed, move the solution to 2 to 8 °C, finish it inside 28 days, and use aliquots so the stock is not handled repeatedly. Powder and solution stability are compared in our storage guide.
TH9507 is the code in development papers, tesamorelin acetate is the acetate salt, and Egrifta is the brand recorded by regulators. The chemical description runs as N-(trans-3-hexenoyl)-GHRH (1-44) amide, or in looser terms a stabilised analogue of human GRF.
The target is GHRHR, the GHRH receptor on pituitary somatotrophs. Downstream, papers abbreviate growth hormone to GH and insulin-like growth factor 1 to IGF-1, the liver-derived marker most studies track. Names vary, but the identity check never does, namely 44 residues with a mass close to 5135.9 g/mol. Whichever name your protocol uses, order it here as tesamorelin in a 5, 10 or 20 mg vial.
Unprotected and active for only minutes, sermorelin is the native GHRH (1-29) amide, sold as a 10 mg vial. The longer molecule keeps 15 further residues plus the protective cap, so enzymes find it far harder to break down. Studies needing the raw fragment as a control therefore point to sermorelin, while studies of the hormone in full point here. Both arrive as powder and are mixed in the same way.
Prefer a ghrelin receptor signal in the same glass? The tesamorelin and ipamorelin blend carries 13 mg plus 3 mg.
The human GHRH chain in full, 44 residues, with a hexenoyl cap on residue one. Cleavage slows down and receptor binding carries on unchanged, and it is in stock now.
Buy bacteriostatic water separately as the diluent.
Labs buy it for receptor activation at GHRHR, growth hormone pulsing and the IGF-1 axis, confined to in vitro laboratory work.
Sermorelin is the bare 29-residue fragment, active for minutes. This molecule is longer, capped and much harder to break down.
Store sealed vials at -20 °C. Mixed material stays at 2 to 8 °C, divided into aliquots, and is finished inside 28 days.
HPLC and mass spectrometry run on every lot, with the certificate open in the COA library before you order.
Select 5 mg, 10 mg or 20 mg here, drop the vial into your cart and pay. Since the vial holds only powder, remember bacteriostatic water.
Look for two things, local dispatch and a lot certificate published before you pay. In research terms the best tesamorelin peptide is simply the one whose mass and purity you can check against your own vial label. AminoLab has no physical shop, trades online, and ships identical tested lots nationwide.
Yes. Every lot is checked by mass spectrometry against an expected 5135.9 g/mol, with purity measured by HPLC. The certificate that results carries your vial's lot number and stays available in the COA library at any point, purchase or no purchase.
Pick this compound where the subject is the whole 44-residue GHRH sequence in a form enzymes cannot quickly destroy. Pick sermorelin, a 10 mg vial, where an unmodified 29-residue fragment is wanted as a control or for repeating older work. Buying both gives a direct comparison.
Most first orders take the 10 mg vial. A 5 mg vial keeps the outlay low for a pilot. Choose whatever your lab can finish within 28 days of mixing, since solution keeps less well than powder.
For comparison work the best peptides to stack with tesamorelin are ipamorelin, which contributes a ghrelin receptor signal, plus sermorelin or CJC-1295 No DAC as shorter GHRH controls. The tesamorelin and ipamorelin blend already pairs the first two at 13 mg to 3 mg. Everything is sold for laboratory research only.
10 mg vial
10 mg vial
5 mg vial
10 mg vial
Research use onlyAminoLab supplies research compounds for laboratory and in-vitro use, not for human or animal consumption. By continuing you confirm you are 18 or older and buying for research.
Leave